Ivermectin News and Research

RSS
Ivermectin (22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b) is a broad-spectrum antiparasitic medication. It is traditionally used against worms, but more recently found to be effective against mites and some lice too. Ivermectin is currently being used to help eliminate river blindness (onchocerciasis) in the Americas and stop transmission of lymphatic filariasis around the world.
New survey shows increase in COVID-19 vaccine acceptance across 23 countries in 2022

New survey shows increase in COVID-19 vaccine acceptance across 23 countries in 2022

Can ivermectin improve the duration of sustained recovery among COVID-19 outpatients?

Can ivermectin improve the duration of sustained recovery among COVID-19 outpatients?

Study finds a lower compliance rate with recently released guidelines for COVID-19 care

Study finds a lower compliance rate with recently released guidelines for COVID-19 care

Exploring antiviral drug combinations for SARS-CoV-2 suppression

Exploring antiviral drug combinations for SARS-CoV-2 suppression

Ivermectin is ineffective in non-severe COVID-19 patients according to new study

Ivermectin is ineffective in non-severe COVID-19 patients according to new study

In silico studies identify potent plant metabolites capable of inhibiting SARS-CoV-2

In silico studies identify potent plant metabolites capable of inhibiting SARS-CoV-2

Antibody drugs are not recommended for patients with covid-19, say WHO experts

Antibody drugs are not recommended for patients with covid-19, say WHO experts

The war in Ukraine and resulting massive population displacement has enhanced epidemic typhus risk

The war in Ukraine and resulting massive population displacement has enhanced epidemic typhus risk

The effectiveness of three repurposed drugs in preventing serious SARS-CoV-2 infection in non-hospitalized adults

The effectiveness of three repurposed drugs in preventing serious SARS-CoV-2 infection in non-hospitalized adults

Should siRNA-based antivirals be added to the COVID toolbox?

Should siRNA-based antivirals be added to the COVID toolbox?

A cancer patient who had SARS-CoV-2 for over eight months

A cancer patient who had SARS-CoV-2 for over eight months

Updated Cochrane Review: No evidence to support the use of ivermectin for treating COVID-19 infection

Updated Cochrane Review: No evidence to support the use of ivermectin for treating COVID-19 infection

Q&A: COVID-19 pandemic has widened gender inequities in health

Q&A: COVID-19 pandemic has widened gender inequities in health

Google search data could predict new COVID-19 cases

Google search data could predict new COVID-19 cases

Anti-vaccine ideology gains ground as lawmakers seek to erode rules for kids’ shots

Anti-vaccine ideology gains ground as lawmakers seek to erode rules for kids’ shots

Why cheap, older drugs that might treat covid never get out of the lab

Why cheap, older drugs that might treat covid never get out of the lab

COVID-19 study proves ivermectin ineffective

COVID-19 study proves ivermectin ineffective

Exploring biomedical literature and clinical trial records to identify new drug combinations for COVID-19 treatment

Exploring biomedical literature and clinical trial records to identify new drug combinations for COVID-19 treatment

Over a third vaccinated-but-unboosted adults have reservations about vaccinating children

Over a third vaccinated-but-unboosted adults have reservations about vaccinating children

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.